title: Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer.
abstract: OBJECTIVE
  To evaluate the treatment results of low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy (ISBT) for T3 mobile tongue cancer.
  
  
  METHODS
  Between 1974 and 1992, 61 patients with T3 mobile tongue cancer were treated with LDR ISBT using (192)Ir hairpins with or without single pins. In addition, between 1991 and 1999, 14 patients were treated with HDR ISBT. For nine patients treated with ISBT alone, the total dose was 59-94 Gy (median 72 Gy) within one week in LDR ISBT and 60 Gy/10 fractions/5 days in HDR ISBT. For 66 patients treated with a combination therapy of external beam radiotherapy (EBRT) and ISBT, the total dose was 12.5-60 Gy (median 30 Gy) of EBRT and 50-112 Gy (median 68 Gy) within 1 week in LDR ISBT or 32-60 Gy (median 48 Gy)/8-10 fractions/5-7 days in HDR ISBT.
  
  
  RESULTS
  The 2- and 3-year local control rates of all patients were both 68%. The 2- and 3-year local control rates of patients treated with LDR ISBT were both 67%, and those with HDR ISBT were both 71%. The local control rate of patients treated with HDR ISBT was similar to those with LDR ISBT.
  
  
  CONCLUSIONS
  ISBT for T3 mobile tongue cancer is effective and acceptable. The treatment result of HDR ISBT is almost similar to that of LDR ISBT for T3 mobile tongue cancer.
authors.affiliation: Department of Oral and Maxillofacial Radiology, Division of Oral Developmental Biology, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka 565-0871, Japan.
authors.forename: Naoya
authors.initials: N
authors.lastname: Kakimoto
authors.forename: Takehiro
authors.initials: T
authors.lastname: Inoue
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Inoue
authors.forename: Shumei
authors.initials: S
authors.lastname: Murakami
authors.forename: Souhei
authors.initials: S
authors.lastname: Furukawa
authors.forename: Ken
authors.initials: K
authors.lastname: Yoshida
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Eiichi
authors.initials: E
authors.lastname: Tanaka
authors.forename: Kimishige
authors.initials: K
authors.lastname: Shimizutani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D005260:Female; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011832:Radiation Injuries; D011879:Radiotherapy Dosage; D015996:Survival Rate; D014062:Tongue Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D007496:Iridium Radioisotopes